MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Congestive Heart Failure (CHF)
Athersys, Inc. (NASDAQ: ATHX)
Organization & Developments: Athersys
Parents
Athersys, Inc. (NASDAQ: ATHX)
Children
2010: RTI Biologics has secured licensing rights to use Athersys' multipoint adult progenitor cell technology (2010)
2014: Athersys secured some 60 patents last year covering its products in more than two dozen countries, including Japan
2014: Stem cell company Athersys eyes potential new opportunities for its stroke therapy in Japan
2016: Top Stock Idea For 2016? - Athersys, A Beaten Down Stem Cell Stock With Great Upside - Athersys, Inc. (NASDAQ:ATHX)
2017: Athersys: Initiating Coverage With Buy Rating And Price Target Of $8 - Athersys, Inc. (NASDAQ:ATHX)
2018: Selling Into A Void - Athersys Moves In Ignorance_seekingalpha.com
2019: Athersys Corp. (ATHX) is within 9 months of seeing pivotal results in Japan in ischemic stroke and possibly acute respiratory distress syndrome and has very encouraging data for these indications in pre-clinical work and completed Phase II clinical trials.
2020: 5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy
2020: Athersys: Stem Cell Opportunity For Risk Tolerant Investors
2021: Athersys Shares Are Ready To Rumble Following Period Of Turmoil
2021: Athersys: Stem Cell Opportunity For Risk-Tolerant Investors - Q1 2021 Update
2021: The Outlook For Athersys Stock
2022: Athersys’ woes continue as Aspire Capital axes its relationship with the biotech
2022: Days after disclosing trial flop, stem cell therapy developer axes 70% of workforce while searching for cash
Developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and
MultiStem, an off-the-shelf stem cell treatment derived from the bone marrow of adults or other non-embryonic sources
The RTI agreement entitles Athersys to get a $3 million payment and as much as $37.5 million for future marketing and revenue milestones
TREASURE trial of MultiStem to treat Ischemic stroke
Jumps
*Key People: Athersys
Finance & Acquisitions: Athersys